Sponsored

Imugene to Deliver Presentations on HER-Vaxx and CF33 at AACR Annual Meeting 2021

Summary

  • Imugene Limited (ASX:IMU) will present HER-Vaxx Phase 2 data and oncolytic virus data at the AACR 2021 Annual Meeting.
  • Dr Rita Laeufle, Imugene’s Chief Medical Officer, will present on its HER-Vaxx cancer immunotherapy program.
  • City of Hope’s Dr Yanghee Woo will present on the CF33 oncolytic virus program.

Imugene Limited (ASX:IMU) has recently announced that its Chief Medical Officer Dr Rita Laeufle and City of Hope’s Dr Yanghee Woo will deliver presentations on the Company’s products at the 2021 Annual Meeting of the American Association for Cancer Research (AACR). The Virtual AACR Annual Meeting is scheduled to be held in April 2021.

Dr Laeufle will present on Imugene’s HER-Vaxx cancer immunotherapy program, while Dr Woo will present on the Company’s CF33 oncolytic virus program.

City of Hope’s Dr Woo serves as Associate Clinical Professor in the Department of Surgery, as well as Director of Gastroenterology Minimally Invasive Therapy Program. Moreover, Dr Laeufle was appointed as the Chief Medical Officer of Imugene during September quarter 2020 to lead its global clinical development, regulatory and medical monitoring activities.

Must Read: Imugene Appoints Dr Rita Laeufle as its New Chief Medical Officer; Stock Soars 8.5%

Following the update, Imugene shares traded at A$0.11 mid-day, with a rise of ~10 per cent.

Dr Rita Laeufle’s HER-Vaxx Presentation

Dr Laeufle’s presentation on the HER-Vaxx cancer immunotherapy program is entitled as:

The Company’s HER-Vaxx is a B-cell peptide cancer immunotherapy that has been designed for treating tumours with HER-2/neu receptor. These tumours comprise breast, gastric, lung, pancreatic and ovarian cancers. HER-Vaxx is constructed from multiple B cell epitopes obtained from the extracellular domain of HER-2/neu.

Do Not Miss: Imugene Limited’s (ASX:IMU) HER-Vaxx Delivers Promising Results in Phase 2 Interim Analysis

In pre-clinical studies as well as Phase 1 and 2 studies, HER-Vaxx has shown to stimulate a potent polyclonal antibody response to a well-known plus validated cancer target - HER-2/neu.

Dr Yanghee Woo’s CF33 Presentation

Dr Woo’s presentation on the CF33 oncolytic virus program is entitled as:

An internationally recognised surgeon and scientist at the City of Hope, Professor Yuman Fong, developed the CF33 oncolytic virus (OV) in his lab. The City of Hope is a well-known independent research and treatment centre based in California for diabetes, cancer as well as other life-threatening diseases.

CF33 has been developed in two distinct constructs: CheckVacc, which is “armed” with an immune checkpoint inhibitor inserted in the virus and Vaxinia, an unarmed construct.

Imugene is proceeding with the Phase 2 clinical trial of HER-Vaxx, under which the recruitment of all patients has already been completed. Besides, both CheckVacc and Vaxinia constructs are continuing their progress to mark the entry into the clinic.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK